Moleculin Biotech Short Interest Update
Short interest in Moleculin Biotech (MBRX) has changed as of mid-June 2026, reflecting investor sentiment.
June 17, 2026
1 min read
9 views
Source: thelincolnianonline.com
Image: thelincolnianonline.com
As of June 15, 2026, short interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) stood at approximately 1.2 million shares, representing 3.4% of the float, according to data from financial analytics firms. This represents a decrease of 8% from the previous reporting period.
The company, a clinical-stage pharmaceutical firm focused on developing treatments for cancer and neurological diseases, has seen its stock price fluctuate in recent weeks. Analysts attribute the change in short interest to mixed results from ongoing clinical trials and broader market trends in biotech.
Moleculin's lead drug candidate, WP1122, is currently in Phase 2 trials for glioblastoma, with interim data expected later this year. The company has not issued any official statements regarding the short interest update.
❓ Frequently Asked Questions
What is short interest?
Short interest is the number of shares that have been sold short but not yet covered or closed out, often used as a measure of bearish sentiment.
Why did short interest in MBRX decrease?
The decrease of 8% in short interest may reflect reduced bearish sentiment among investors, possibly due to mixed clinical trial results or market trends.
What is Moleculin Biotech's main drug candidate?
Moleculin's lead drug candidate is WP1122, currently in Phase 2 trials for glioblastoma, a type of brain cancer.
